Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression

Cell Death and Differentiation

Volumn 16, Issue 9, 2009, Pages 1289-1299

  Zhu, J Y ^a   Giaisi, M ^a   Kohler R ^a   Muller W W ^a   Muhleisen A ^a   Proksch, P ^b   Krammer, P H ^a   Li Weber, M ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 8; CASPASE 9; CISPLATIN; CONCANAVALIN A; DAUNORUBICIN; FAS LIGAND; FLICE INHIBITORY PROTEIN; FLUOROURACIL; IONOMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BID; ROCAGLAMIDE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOFURANS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE; FAS LIGAND PROTEIN; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; JURKAT CELLS; LEUKEMIA, T-CELL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

AGLAIA;

EID: 69049104101     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2009.42     Document Type: Article

References (40)

1. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605-615.
2. Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G et al Treatment of adult acute lymphoblastic leukemia (ALL): Long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002; 99: 863-871.
3. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM et al Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005; 106: 3760-3767.
4. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 2004; 23: 2950-2966.
5. Galluzzi L, Larochette N, Zamzami N, Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006; 25 4812-4830.
6. Krammer PH, Arnold R, Lavrik I. Life and death in peripheral T cells. Nat Rev Immunol 2007; 7: 532-542.
7. Klas C, Debatin KM, Jonker RR, Krammer PH. Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 1993; 5 625-630.
8. Brenner D, Krammer PH, Arnold R. Concepts of activated T cell death. Crit Rev Oncol Hematol 2008; 66: 52-64.
9. Ogasawara J, Suda T, Nagata S. Selective apoptosis of CD4+CD8+ thymocytes by the anti-Fas antibody. J Exp Med 1995; 181: 485-491.
10. Li-Weber M, Krammer PH. Function and Regulation of CD95 (APO-1/Fas) Ligand in the Immune System. Semin Immunol 2003; 15: 145-157.
11. Budd RC, Yeh WC, Tschopp J. cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol 2006; 6: 196-204.
12. Zaichuk TA, Shroff EH, Emmanuel R, Filleur S, Nelius T, Volpert OV. Nuclear factor of activated T cells balances angiogenesis activation and inhibition. J Exp Med 2004; 199: 1513-1522.
13. Ueffing N, Schuster M, Keil E, Schulze-Osthoff K, Schmitz I. Up-regulation of c-FLIP short by NFAT contributes to apoptosis resistance of short-term activated T cells. Blood 2008; 112: 690-698.
14. Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001; 21: 3964-3973.
15. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 2001; 21 5299-5305.
16. Kirchhoff S, Muller WW, Krueger A, Schmitz I, Krammer PH. TCR-mediated up-regulation of c-FLIPshort correlates with resistance toward CD95-mediated apoptosis by blocking death-inducing signaling complex activity. J Immunol 2000; 165: 6293-6300.
17. Schmitz I, Weyd H, Krueger A, Baumann S, Fas SC, Krammer PH et al. Resistance of short term activated T cells to CD95-mediated apoptosis correlates with de novo protein synthesis of c-FLIPshort. J Immunol 2004; 172: 2194-2200.
18. Zhang N, Hopkins K, He YW. c-FLIP protects mature T lymphocytes from TCR-mediated killing. J Immunol 2008; 181: 5368-5373.
19. Kim S, Salim AA, Swanson SM, Kinghorn AD. Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy. Anticancer Agents Med Chem 2006; 6: 319-345.
20. Zhu JY, Lavrik IN, Mahlknecht U, Giaisi M, Proksch P, Krammer PH et al. The tradition Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of MAPK activities. Int J Cancer 2007; 121: 1839-1846.
21. Proksch P, Giaisi M, Treiber MK, Palfi K, Merling A, Spring H et al Rocaglamide derivatives are immunosuppressive phytochemicals that target NF-AT activation in T cells. J Immunol 2005; 174: 7075-7084.
22. Eichhorst ST, Muller M, Li-Weber M, Schulze-Bergkamen H, Angel P, Krammer PH. A novel AP-1 element in the CD95 Ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol Cell Biol 2000; 20: 7826-7837.
23. Baumann S, Hess J, Eichhorst ST, Krueger A, Angel P, Krammer PH et al An unexpected role for FosB in activation-induced cell death of T cells. Oncogene 2003; 22: 1333-1339.
24. Lee SK, Cui B, Mehta RR, Kinghorn AD, Pezzuto JM. Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta[b]benzofuran lignans isolated from Aglaia elliptica. Chem Biol Interact 1998; 115 215-218.
25. Umezawa K, Yamamoto T, Koyano T. Suppressant for cancer gene function. Japanese Patent JP 9067375(A) 1997.
26. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997; 15: 707-747.
27. Gómez del Arco P, Martínez-Martínez S, Maldonado JL, Ortega-Pérez I, Redondo JM. A role for the p38 MAP kinase pathway in the nuclear shuttling of NFATp. J Biol Chem 2000; 275: 13872-13878.
28. Chow CW, Dong D, Flavell RA, Davís RJ. c-Jun NH(2)-terminal kinase inhibits targeting of the protein phosphatase calcineurin to NFATc1. Mol Cell Biol 2000; 20: 5227-5234.
29. Li-Weber M, Laur O, Krammer PH. Novel Egr/NF-AT composite sites mediate activation of the CD95 (APO-1/Fas) ligand promoter in response to T-cell stimulation. Eur J Immunol 1999; 29: 3017-3027.
30. Loh C, Carew JA, Kim J, Hogan PG, Rao A. T-cell receptor stimulation elicits an early phase of activation and a later phase of deactivation of the transcription factor NFAT1. Mol Cell Biol 1996; 16: 3945-3954.
31. Kasibhatla S, Brunner T, Genestier L, Echeverri F. Mahboubi A and Green DR, DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1998; 1: 543-551.
32. Gao M, Karin M. Regulating the regulators: Control of protein ubiquitination and ubiquitin-like modifications by extracellular stimuli. Mol Cell 2005; 19: 581-593.
33. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K et al. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 2006; 124: 601-613.
34. King ML, Chiang CC, Ling HC, Fujita E, Ochiai M, McPhail AT. X-ray crystal structure of rocaglamide, a novel antileukemic 1H-cyclopenta[b]benzofuran from Aglaia elliptifolia. J Chem Soc, Chem Commun 1982: 1150-1151.
35. Hwang BY, Su BN, Chai H, Mi Q, Kardono LB, Afriastini JJ et al. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. J Org Chem 2004; 69: 3350-3358.
36. Vermes I, Haanen C, Reutelingsperger C. Flow cytometry of apoptotic cell death. J Immunol Methods 2000; 243: 167-190.
37. Scaffidi C, Medema JP, Krammer PH, Peter ME. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/ b. J Biol Chem 1997; 272: 26953-26958.
38. Trauth BC, Klas C, Peters AM, Matzku S, Möller P, Falk W et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-305.
39. Krueger A, Fas SC, Giaisi M, Bleumink M, Merling A, Stumpf C et al HTLV-1 Tax protects against CD95-mediated apoptosis by induction of the cellular FLICE-inhibitory protein (c-FLIP). Blood 2006; 107 3933-3939.
40. Mattern J, Bak M, Hahn EW, Volm M. Human tumor xenografts as model for drug testing. Cancer Metastasis Rev 1998; 7: 263-284.